Belite Bio Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting
Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical company focusing on degenerative retinal diseases, has announced its participation in the American Academy of Ophthalmology Annual Meeting (AAO 2024) from October 18-21, 2024, in Chicago. The company will present data from its completed Phase II adolescent Stargardt disease trial.
Two presentations are scheduled:
- A podium presentation titled "Tinlarebant (LBS-008) for Adolescents with Stargardt Disease" by Dr. Quan Dong Nguyen on October 19, 2024, at 10:33 AM CDT.
- An e-poster presentation titled "Investigation of an Oral Retinol Binding Protein 4 Antagonist in the Treatment of Childhood-onset Stargardt Disease" by Dr. Nathan L Mata, available on-demand.
These presentations will showcase Belite Bio's progress in developing novel therapeutics for Stargardt disease, a degenerative retinal condition with significant unmet medical needs.
Belite Bio, Inc (NASDAQ: BLTE), un'azienda biofarmaceutica in fase clinica con focus sulle malattie retiniche degenerative, ha annunciato la sua partecipazione al Meeting Annuale dell'Accademia Americana di Oftalmologia (AAO 2024) che si svolgerà dal 18 al 21 ottobre 2024 a Chicago. L'azienda presenterà i dati del suo completato trial di Fase II sulla malattia di Stargardt in adolescenti.
Due presentazioni sono programmate:
- Una presentazione al podio intitolata
Belite Bio, Inc (NASDAQ: BLTE), una empresa biofarmacéutica en etapa clínica que se centra en las enfermedades retinianas degenerativas, ha anunciado su participación en el Encuentro Anual de la Academia Americana de Oftalmología (AAO 2024) del 18 al 21 de octubre de 2024 en Chicago. La empresa presentará datos de su ensayo de Fase II sobre la enfermedad de Stargardt en adolescentes.
Se están programando dos presentaciones:
- Una presentación en el podio titulada
Belite Bio, Inc (NASDAQ: BLTE), 퇴행성 망막 질환에 집중하는 임상 단계의 생물 의약품 회사가 2024년 10월 18일부터 21일까지 시카고에서 열리는 미국 안과학회 연례 회의 (AAO 2024)에 참여한다고 발표했습니다. 이 회사는 완료된 청소년 스타가르트 질환에 대한 2상 시험의 데이터를 발표할 예정입니다.
두 가지 발표가 예정되어 있습니다:
- 2024년 10월 19일 CDT 오전 10시 33분에 Dr. Quan Dong Nguyen이 발표하는
Belite Bio, Inc (NASDAQ: BLTE), une société bio-pharmaceutique en phase clinique axée sur les maladies dégénératives de la rétine, a annoncé sa participation à la Réunion Annuelle de l'Académie Américaine d'Ophthalmologie (AAO 2024) qui se déroulera du 18 au 21 octobre 2024 à Chicago. L'entreprise présentera des données issues de son essai de Phase II sur la maladie de Stargardt chez les adolescents.
Deux présentations sont prévues :
- Une présentation sur podium intitulée
Belite Bio, Inc (NASDAQ: BLTE), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf degenerative Netzhauterkrankungen spezialisiert hat, kündigte seine Teilnahme an der Jahrestagung der American Academy of Ophthalmology (AAO 2024) an, die vom 18. bis 21. Oktober 2024 in Chicago stattfindet. Das Unternehmen wird Daten aus seiner abgeschlossenen Phase-II-Studie zur Stargardt-Erkrankung bei Jugendlichen präsentieren.
Zwei Präsentationen sind geplant:
- Eine Podiumspräsentation mit dem Titel
- Presentation of completed Phase II trial data for adolescent Stargardt disease
- Participation in a major ophthalmology conference (AAO 2024)
- Potential exposure to industry experts and investors
- None.
SAN DIEGO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the Company will present data from its completed Phase II adolescent Stargardt disease trial at the American Academy of Ophthalmology Annual Meeting (AAO 2024) being held October 18-21, 2024, in Chicago, IL.
Podium Presentation:
Title: Tinlarebant (LBS-008) for Adolescents with Stargardt Disease
Presentation Type: Late breaking developments (live broadcast)
Presenting Author: Quan Dong Nguyen, MD, MSc
Session: RET16
Date/Time: Saturday, October 19, 2024; 10:33 AM – 10:40 AM CDT
Location: Arie Crown Theater (Lakeside Center building, 1F), Chicago, IL
E-poster Presentation
Title: Investigation of an Oral Retinol Binding Protein 4 Antagonist in the Treatment of Childhood-onset Stargardt Disease
Presenting Author: Nathan L Mata, PHD
Date/Time: On-demand
About Tinlarebant (a/k/a LBS-008)
Tinlarebant is a novel oral therapy that is intended to reduce the accumulation of vitamin A-based toxins (known as bisretinoids) that cause retinal disease in Stargardt Disease type 1 (STGD1) and also contribute to disease progression in geographic atrophy, or advanced dry age-related macular degeneration (AMD). Bisretinoids are by-products of the visual cycle, which is dependent on the supply of vitamin A (retinol) to the eye. Tinlarebant works by reducing and maintaining levels of serum retinol binding protein 4 (RBP4), the sole carrier protein for retinol transport from the liver to the eye. By modulating the amount of retinol entering the eye, Tinlarebant reduces the formation of bisretinoids. Tinlarebant has been granted Fast Track Designation and Rare Pediatric Disease designation in the U.S., Orphan Drug Designation in the U.S. Europe, and Japan, and Sakigake Designation in Japan for the treatment of STGD1.
Stargardt Disease (STGD1)
STGD1 is the most common inherited macular dystrophy (causing blurring or loss of central vision) in both adults and children. The disease is caused by mutations in a retina-specific gene (ABCA4), which results in progressive accumulation of bisretinoids leading to retinal cell death and progressive loss of central vision. The fluorescent properties of bisretinoids and the development of retinal imaging systems have helped ophthalmologists identify and monitor disease progression. Currently, there are no FDA approved treatments for STGD1.
Importantly, the appearance of bisretinoids, followed by retinal cell death, and progressive loss of vision is also observed in geographic atrophy (GA) patients. Therefore, Belite Bio is evaluating safety and efficacy of Tinlarebant in GA patients in a 2-year Phase 3 study (PHOENIX).
About Belite Bio
Belite Bio is a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt Disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Safety and efficacy of Belite’s lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of vitamin A-based toxins in the eye, is currently being evaluated in three late-stage clinical trials. In STGD1, a 2-year, Phase 3 study (DRAGON) and a 2-year, Phase 2/3 study (DRAGON II) in adolescent STGD1 subjects are currently ongoing. In GA, a 2-year, Phase 3 study (PHOENIX) is ongoing. For more information, follow us on Twitter, Instagram, LinkedIn, Facebook or visit us at www.belitebio.com.
Forward Looking Statements
This press release contains forward-looking statements about future expectations and plans, as well as other statements regarding matters that are not historical facts. These statements include but are not limited to statements regarding the potential implications of clinical data for patients, and Belite Bio’s advancement of, and anticipated preclinical activities, clinical development, regulatory milestones, and commercialization of its product candidates, and any other statements containing the words “expect”, “hope” and similar expressions. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including but not limited to Belite Bio’s ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may not support further development or regulatory approval; the timing to complete relevant clinical trials and/or to receive the interim/final data of such clinical trials; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of Belite Bio’s drug candidates; the potential efficacy of Tinlarebant, as well as those risks more fully discussed in the “Risk Factors” section in Belite Bio’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Belite Bio, and Belite Bio undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.
Media and Investor Relations Contact:
Jennifer Wu / ir@belitebio.com
Julie Fallon / belite@argotpartners.com
FAQ
What data will Belite Bio (BLTE) present at the AAO 2024 meeting?
When and where will Belite Bio's (BLTE) podium presentation take place at AAO 2024?
What is the focus of Belite Bio's (BLTE) e-poster presentation at AAO 2024?